Published January 1, 2022
| Version v1
Journal article
Open
PENTRAXIN 3 LEVELS CORRELATE WELL WITH DISEASE SEVERITY AT ADMISSION IN COVID-19 PATIENTS
Creators
- 1. Univ Hlth Sci, Kosuyolu High Specializat Res & Training Hosp, Dept Infect Dis, Istanbul, Turkey
- 2. Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Res & Training Hosp, Dept Infect Dis, Istanbul, Turkey
- 3. Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Res & Training Hosp, Dept Internal Med, Istanbul, Turkey
- 4. Univ Hlth Sci, Kartal Dr Lutfi Kirdar City Hosp, Dept Internal Med, Istanbul, Turkey
- 5. Univ Hlth Sci, Kosuyolu High Specializat Res & Training Hosp, Dept Cardiol, Istanbul, Turkey
- 6. Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Res & Training Hosp, Dept Biochem, Istanbul, Turkey
- 7. Univ Hlth Sci, Dept Immunol, Istanbul, Turkey
Description
Pentraxin 3 (PTX3), a long pentraxin, is not only released from dendritic cells and neutrophils but also from epithelial and endothelial cells such as alveolar epithelium. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initially activates the innate immune system, causing a complex immune response. Clinical and experimental studies suggest that PTX3, a locally and systemically secreted marker, can be used as a predictor of the severity and mortality in respiratory infections. In the current study, serum PTX3 levels in patients hospitalized with COVID-19 were found to be significantly increased at admission and showed significant association with the disease severity.
Files
bib-6764bd20-0465-4b1a-be2f-c62e9aa5b79d.txt
Files
(233 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:53b30bf64ce45de648b295b830e75591
|
233 Bytes | Preview Download |